Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant

Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?

(2016) Alexander Kadokura et al.   HUMAN PATHOLOGY

Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes

(2016) Shi Yang et al.   MELANOMA RESEARCH

Desmoplastic melanoma: C>Ts and NF-κB

(2016) Roy Rabbie et al.   Pigment Cell & Melanoma Research

Desmoplastic Melanoma, Neurotropism, and Neurotrophin Receptors—What We Know and What We Do Not

(2015) Noah Frydenlund et al.   ADVANCES IN ANATOMIC PATHOLOGY

Neurotrophin receptors and perineural invasion in desmoplastic melanoma

(2015) Noah Frydenlund et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck

(2015) Julia Thierauf et al.   MELANOMA RESEARCH

Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis

(2015) Stephan W Jahn et al.   MODERN PATHOLOGY

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases

(2015) Hojabr Kakavand et al.   MODERN PATHOLOGY

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

(2015) A Hunter Shain et al.   NATURE GENETICS

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

(2014) D. Massi et al.   ANNALS OF ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

(2014) Jason Madore et al.   Pigment Cell & Melanoma Research

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation

(2014) N. Rodi  et al.   Cancer Immunology Research

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Desmoplastic melanoma: A review

(2012) Lucy L. Chen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Incidence and survival of desmoplastic melanoma in the United States, 1992-2007

(2011) Zhuang Feng et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal

(2011) Daniel D Miller et al.   MODERN PATHOLOGY

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis

(2008) Evan George et al.   JOURNAL OF CUTANEOUS PATHOLOGY